“Countries coming together in this way shows a unity of purpose and resolve to end the acute phase of this pandemic, and we must now work closely with vaccine manufacturers—who play an integral part in the global response—to put in place the agreements needed to fulfil COVAX’s core aim: to have two billion vaccine doses available by the end of 2021.
The success of COVAX hinges not only on economies signing up to the COVAX Facility and commitments from vaccine manufacturers, but also filling key funding gaps for both COVAX research and development (R&D) work and the Gavi COVAX AMC to support participation of lower income economies in the COVAX Facility.
Governments, vaccine manufacturers (in addition to their own R&D), organisations and individuals have committed US$ 1.4 billion towards vaccine R&D so far, but a further US$ 700-800 million is urgently needed to continue to move the portfolio forward in addition to US$ 300 million to fund WHO’s SOLIDARITY trial.
The Gavi COVAX AMC has raised around US$ 700 million from sovereign donors as well as philanthropy and the private sector, against an initial target of US$ 2 billion in seed funding needed by the end of 2020.
5606
为该机制提供资金对于确保支付能力不会成为获取COVID-19疫苗的障碍至关重要。
Funding the Gavi COVAX AMC will be critical to ensuring ability to pay is not a barrier to accessing COVID-19 vaccines, a situation which would leave the majority of the world unprotected, with the pandemic and its impact continuing unabated.
5607
承诺协议还要求收入较高国家的政府在2020年10月9日之前为储备剂量预付资金。
The Commitment Agreements also commit higher income governments to provide an upfront payment to reserve doses by 9 October 2020.
These funds will be used to accelerate the scale-up of vaccine manufacturing to secure two billion doses of vaccine, enough to vaccinate one billion people assuming the vaccine requires a two-dose regimen.
5609
关于这些预付款的进一步细节可以在全球疫苗免疫联盟COVID-19疫苗全球获取机制介绍材料中找到。
Further details on these upfront payments are available in Gavi’s COVAX Facility Explainer.
5610
除为参与经济体采购外，全球获取机制还将为紧急和人道主义使用维持缓冲剂量。
As well as procuring doses for participating economies, the COVAX Facility will also maintain a buffer of doses for emergency and humanitarian use.